Skip to main content
search

May 21, 2026

We’re modernizing the Chemaxon Academic Program and retiring Chemicalize as we continue to invest in Marvin Cloud – our next-generation, browser-based chemical sketching platform.

These updates allow us to provide a faster, more powerful, and more unified drawing experience that better supports today’s research and teaching workflows.

Academic Program update

As part of this change, free individual academic licenses are discontinued.

  • Existing licenses will remain active until July 31, 2026
  • After this date, access will end in line with the End User License Agreement

We understand this is a significant shift. While Marvin Cloud is a paid subscription*, it is designed with flexible pricing tiers to support individual researchers and educators.

We continue to support the academic community through:

  • Marvin Cloud, available with a 14-day free trial
  • Academic discounts for institutions and not-for-profit research

Lear more about our options for Academia here.

Chemicalize retirement

Chemicalize will be retired on June 30, 2027 as we transition to Marvin Cloud.

  • Yearly subscriptions: cannot be renewed after the current term
  • Monthly subscriptions: cannot be renewed after July 31, 2026

We’re committed to making this transition as smooth as possible and to continuing to support scientists, educators, and researchers with modern, accessible solutions.

Explore Marvin Cloud by starting your 14-day free trial.

*Online payment in Marvin Cloud is currently available in the US, European Union, United Kingdom, and Switzerland.

About Certara

Chemaxon is a leading cheminformatics company that provides platforms, applications, and solutions to handle chemical entities in life sciences, biotechnology and other research industries. Certara acquired Chemaxon in 2024 to close gaps in the design-make-test-analyze cycle, bring promising leads into biosimulation, and speed up the launch of new medicines. Certara accelerates medicines using biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include more than 2,600 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries.